Zacks Research Issues Positive Estimate for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Zacks Research increased their Q4 2025 EPS estimates for shares of Bruker in a note issued to investors on Thursday, March 6th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.96 per share for the quarter, up from their prior estimate of $0.92. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q1 2026 earnings at $0.53 EPS and Q4 2026 earnings at $1.07 EPS.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.

A number of other equities analysts have also recently commented on BRKR. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a research report on Thursday, December 5th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a report on Monday, February 24th. Barclays lowered their price target on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. UBS Group assumed coverage on Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective for the company. Finally, Bank of America upped their target price on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Bruker Stock Down 3.9 %

BRKR stock opened at $45.56 on Monday. Bruker has a 1-year low of $44.89 and a 1-year high of $94.86. The business’s 50 day simple moving average is $54.48 and its 200 day simple moving average is $58.76. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $6.91 billion, a PE ratio of 59.95, a PEG ratio of 2.16 and a beta of 1.18.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Monday, March 17th. Bruker’s dividend payout ratio is currently 26.32%.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Bruker by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after purchasing an additional 177 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock worth $75,000 after purchasing an additional 196 shares during the period. Insigneo Advisory Services LLC grew its stake in Bruker by 4.7% during the fourth quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company’s stock worth $286,000 after buying an additional 218 shares in the last quarter. Arizona State Retirement System increased its holdings in Bruker by 0.7% in the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock valued at $1,801,000 after buying an additional 222 shares during the period. Finally, CIBC Asset Management Inc raised its position in shares of Bruker by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock valued at $248,000 after buying an additional 223 shares in the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.